跳至主要内容
临床试验/NCT01226914
NCT01226914已完成不适用

A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy

Medical University of South Carolina0 个研究点目标入组 55 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
55
主要终点
To Compare the Amount of Post-operative Wound Drainage Between the Group of Patients in Which EVICEL™ Spray is Utilized (Arm A), and the Group of Patients in Which an EVICEL™ Placebo is Utilized (Arm B).

研究概览

简要总结

Primary Objectives

  • To compare the amount of post-operative wound drainage between the group of patients in which EVICEL™ spray is utilized (Arm A), and the group of patients in which an EVICEL™ placebo is utilized (Arm B).
  • To compare the length of time to drain removal between Arm A and Arm B. Secondary objectives
  • To compare the incident or rates of seroma, hematoma, and post-operative edema between the two groups.
  • To compare the reported pain experienced in each group at selected time points using a standard numerical rating scale (NRS).
  • To compare the length of hospital stay between the two groups of patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Placebo

Placebo Comparator

For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.

干预措施: EVICEL (Drug)

Evicel

Experimental

For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.

干预措施: EVICEL (Drug)

结局指标

主要结局

To Compare the Amount of Post-operative Wound Drainage Between the Group of Patients in Which EVICEL™ Spray is Utilized (Arm A), and the Group of Patients in Which an EVICEL™ Placebo is Utilized (Arm B).

时间窗: 90 days

First 8 hours output (mL), Total output (mL), Drain time (hours), Hospital stay (hours), AEs

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shaun A. Nguyen

Associate Professor - Director of Clinical Research

Medical University of South Carolina

相似试验